Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906101 | 0.86 | HTR2C (0.40) | HTR2CHTR2AHTR2BKCNH2KDM4E | |
| SCHEMBL905836 | 0.86 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL906119 | 0.86 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL906122 | 0.86 | HTR2C (0.39) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL906015 | 0.85 | HTR2C (0.40) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL6182149 | 0.85 | HTR2C (0.40) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL237951 | 0.83 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2SSTR4 | |
| SCHEMBL905805 | 0.83 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2SSTR1 | |
| SCHEMBL2639684 | 0.83 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2SSTR4 | |
| SCHEMBL5585330 | 0.83 | HTR2C (0.41) | HTR2CHTR2AHTR2BKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | claimed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | HTR2C 7/4885HTR2A 14/4885HTR2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.